{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T10:12:07Z","timestamp":1790417527652,"version":"4.1.0"},"reference-count":48,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.vaccine.2021.01.040","type":"journal-article","created":{"date-parts":[[2021,1,30]],"date-time":"2021-01-30T15:42:18Z","timestamp":1612021338000},"page":"1435-1444","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Single-dose intranasal subunit vaccine rapidly clears secondary sepsis in a high-dose pneumonic plague infection"],"prefix":"10.1016","volume":"39","author":[{"given":"Christina","family":"D'Arco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison A.","family":"McCormick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul M.","family":"Arnaboldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.vaccine.2021.01.040_b0005","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1128\/CMR.10.1.35","article-title":"Yersinia pestis\u2013etiologic agent of plague","volume":"10","author":"Perry","year":"1997","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.vaccine.2021.01.040_b0010","unstructured":"WHO. Plague Outbreak Madagascar. World Health Organization Regional Office for Africa 2017."},{"issue":"3","key":"10.1016\/j.vaccine.2021.01.040_b0015","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1099\/jmm.0.000915","article-title":"The rise of pneumonic plague in Madagascar: current plague outbreak breaks usual seasonal mould","volume":"68","author":"Rabaan","year":"2019","journal-title":"J Med Microbiol"},{"key":"10.1016\/j.vaccine.2021.01.040_b0020","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.epidem.2018.05.001","article-title":"The 2017 plague outbreak in Madagascar: Data descriptions and epidemic modelling","volume":"25","author":"Nguyen","year":"2018","journal-title":"Epidemics"},{"issue":"5","key":"10.1016\/j.vaccine.2021.01.040_b0025","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S1473-3099(18)30730-8","article-title":"Epidemiological characteristics of an urban plague epidemic in Madagascar, August-November, 2017: an outbreak report","volume":"19","author":"Randremanana","year":"2019","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2021.01.040_b0030","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3201\/eid0701.010106","article-title":"Transferable plasmid-mediated resistance to streptomycin in a clinical isolate of Yersinia pestis","volume":"7","author":"Guiyoule","year":"2001","journal-title":"Emerg Infect Dis"},{"issue":"10","key":"10.1016\/j.vaccine.2021.01.040_b0035","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1056\/NEJM199709043371004","article-title":"Multidrug resistance in Yersinia pestis mediated by a transferable plasmid","volume":"337","author":"Galimand","year":"1997","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.vaccine.2021.01.040_b0040","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0000309","article-title":"Multiple antimicrobial resistance in plague: an emerging public health risk","volume":"2","author":"Welch","year":"2007","journal-title":"PLoS ONE"},{"issue":"3\u20134","key":"10.1016\/j.vaccine.2021.01.040_b0045","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/j.1574-695X.1995.tb00196.x","article-title":"A new improved sub-unit vaccine for plague: the basis of protection","volume":"12","author":"Williamson","year":"1995","journal-title":"FEMS Immunol Med Microbiol"},{"issue":"17\u201318","key":"10.1016\/j.vaccine.2021.01.040_b0050","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1016\/S0264-410X(96)00151-X","article-title":"Local and systemic immune response to a microencapsulated sub-unit vaccine for plague","volume":"14","author":"Williamson","year":"1996","journal-title":"Vaccine"},{"issue":"10","key":"10.1016\/j.vaccine.2021.01.040_b0055","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/S0264-410X(96)00303-9","article-title":"A sub-unit vaccine elicits IgG in serum, spleen cell cultures and bronchial washings and protects immunized animals against pneumonic plague","volume":"15","author":"Williamson","year":"1997","journal-title":"Vaccine"},{"issue":"2\u20133","key":"10.1016\/j.vaccine.2021.01.040_b0060","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0264-410X(00)00108-0","article-title":"Protection conferred by a fully recombinant sub-unit vaccine against Yersinia pestis in male and female mice of four inbred strains","volume":"19","author":"Jones","year":"2000","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2021.01.040_b0065","doi-asserted-by":"crossref","first-page":"793","DOI":"10.4269\/ajtmh.1998.58.793","article-title":"Short- and long-term efficacy of single-dose subunit vaccines against Yersinia pestis in mice","volume":"58","author":"Anderson","year":"1998","journal-title":"Am J Trop Med Hyg"},{"issue":"11\u201312","key":"10.1016\/j.vaccine.2021.01.040_b0070","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/S0264-410X(98)80110-2","article-title":"Protection against experimental bubonic and pneumonic plague by a recombinant capsular F1-V antigen fusion protein vaccine","volume":"16","author":"Heath","year":"1998","journal-title":"Vaccine"},{"issue":"38","key":"10.1016\/j.vaccine.2021.01.040_b0075","doi-asserted-by":"crossref","first-page":"5708","DOI":"10.1016\/j.vaccine.2019.07.103","article-title":"Robust Th1 cellular and humoral responses generated by the Yersinia pestis rF1-V subunit vaccine formulated to contain an agonist of the CD137 pathway do not translate into increased protection against pneumonic plague","volume":"37","author":"Bowen","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.01.040_b0080","unstructured":"Pitt. Non-human primates as a model for pneumonic plague. Animals Models and Correlates of Protection for Plague Vaccines Workshop 2004."},{"issue":"2","key":"10.1016\/j.vaccine.2021.01.040_b0085","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1586\/14760584.7.2.209","article-title":"Current challenges in the development of vaccines for pneumonic plague","volume":"7","author":"Smiley","year":"2008","journal-title":"Expert Rev Vaccines"},{"issue":"6","key":"10.1016\/j.vaccine.2021.01.040_b0090","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1517\/14712598.4.6.965","article-title":"Yersinia pestis (plague) vaccines","volume":"4","author":"Titball","year":"2004","journal-title":"Expert Opin Biol Ther"},{"issue":"5","key":"10.1016\/j.vaccine.2021.01.040_b0095","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/s41435-019-0065-0","article-title":"Yersinia pestis and plague: an updated view on evolution, virulence determinants, immune subversion, vaccination, and diagnostics","volume":"20","author":"Demeure","year":"2019","journal-title":"Genes Immun"},{"key":"10.1016\/j.vaccine.2021.01.040_b0100","doi-asserted-by":"crossref","unstructured":"Sun W, Singh AK. Plague vaccine: recent progress and prospects. NPJ Vaccines 2019;4:11,9. eCollection 2019.","DOI":"10.1038\/s41541-019-0105-9"},{"issue":"47","key":"10.1016\/j.vaccine.2021.01.040_b0105","doi-asserted-by":"crossref","first-page":"5768","DOI":"10.1016\/j.vaccine.2016.09.063","article-title":"Intranasal delivery of a protein subunit vaccine using a Tobacco Mosaic Virus platform protects against pneumonic plague","volume":"34","author":"Arnaboldi","year":"2016","journal-title":"Vaccine"},{"issue":"33","key":"10.1016\/j.vaccine.2021.01.040_b0110","doi-asserted-by":"crossref","first-page":"4228","DOI":"10.1016\/j.vaccine.2014.04.051","article-title":"Tobacco mosaic virus efficiently targets DC uptake, activation and antigen-specific T cell responses in vivo","volume":"32","author":"Kemnade","year":"2014","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2021.01.040_b0115","article-title":"Humans have antibodies against a plant virus: evidence from tobacco mosaic virus","volume":"8","author":"Liu","year":"2013","journal-title":"PLoS ONE"},{"issue":"6","key":"10.1016\/j.vaccine.2021.01.040_b0120","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0130858","article-title":"Development of a multivalent subunit vaccine against tularemia using tobacco mosaic virus (TMV) based delivery system","volume":"10","author":"Banik","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2021.01.040_b0125","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.3389\/fmicb.2018.01195","article-title":"An improved tobacco mosaic virus (TMV)-conjugated multiantigen subunit vaccine against respiratory tularemia","volume":"9","author":"Mansour","year":"2018","journal-title":"Front Microbiol"},{"issue":"4","key":"10.1016\/j.vaccine.2021.01.040_b0130","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0194614","article-title":"Intranasal administration of a two-dose adjuvanted multi-antigen TMV-subunit conjugate vaccine fully protects mice against Francisella tularensis LVS challenge","volume":"13","author":"McCormick","year":"2018","journal-title":"PLoS ONE"},{"issue":"3","key":"10.1016\/j.vaccine.2021.01.040_b0135","doi-asserted-by":"crossref","first-page":"586","DOI":"10.4161\/hv.27567","article-title":"Single-dose monomeric HA subunit vaccine generates full protection from influenza challenge","volume":"10","author":"Mallajosyula","year":"2014","journal-title":"Hum Vaccin Immunother"},{"issue":"2","key":"10.1016\/j.vaccine.2021.01.040_b0140","first-page":"6","article-title":"Single dose TMV-HA vaccine protects mice from H5N1 influenza challenge","volume":"1","author":"Mallajosyula","year":"2016","journal-title":"Int J Vaccine Res"},{"issue":"26","key":"10.1016\/j.vaccine.2021.01.040_b0145","doi-asserted-by":"crossref","first-page":"5516","DOI":"10.1016\/j.vaccine.2006.04.058","article-title":"Protection of rabbits against cutaneous papillomavirus infection using recombinant tobacco mosaic virus containing L2 capsid epitopes","volume":"24","author":"Palmer","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.01.040_b0150","first-page":"3076","article-title":"Measuring bacterial load and immune responses in mice infected with Listeria monocytogenes","volume":"54","author":"Wang","year":"2011","journal-title":"J Vis Exp"},{"issue":"5","key":"10.1016\/j.vaccine.2021.01.040_b0155","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0217440","article-title":"Shift from primary pneumonic to secondary septicemic plague by decreasing the volume of intranasal challenge with Yersinia pestis in the murine model","volume":"14","author":"Olson","year":"2019","journal-title":"PLoS ONE"},{"issue":"6","key":"10.1016\/j.vaccine.2021.01.040_b0160","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1586\/erv.13.42","article-title":"Live-attenuated Yersinia pestis vaccines","volume":"12","author":"Wang","year":"2013","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2021.01.040_b0165","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1146\/annurev-bioeng-071811-150054","article-title":"Mucosal vaccine design and delivery","volume":"14","author":"Woodrow","year":"2012","journal-title":"Annu Rev Biomed Eng"},{"issue":"4","key":"10.1016\/j.vaccine.2021.01.040_b0170","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/apm.12351","article-title":"Mucosal vaccines: a paradigm shift in the development of mucosal adjuvants and delivery vehicles","volume":"123","author":"Srivastava","year":"2015","journal-title":"APMIS"},{"issue":"1","key":"10.1016\/j.vaccine.2021.01.040_b0175","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1128\/IAI.00559-09","article-title":"Absence of inflammation and pneumonia during infection with nonpigmented Yersinia pestis reveals a new role for the pgm locus in pathogenesis","volume":"78","author":"Lee-Lewis","year":"2010","journal-title":"Infect Immun"},{"issue":"8","key":"10.1016\/j.vaccine.2021.01.040_b0180","doi-asserted-by":"crossref","first-page":"3443","DOI":"10.1128\/IAI.00382-10","article-title":"Biosafety level 2 model of pneumonic plague and protection studies with F1 and Psa","volume":"78","author":"Galvan","year":"2010","journal-title":"Infect Immun"},{"issue":"12","key":"10.1016\/j.vaccine.2021.01.040_b0185","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1128\/CVI.00499-15","article-title":"Intramuscular immunization of mice with a live-attenuated triple mutant of yersinia pestis CO92 induces robust humoral and cell-mediated immunity to completely protect animals against pneumonic plague","volume":"22","author":"Tiner","year":"2015","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2021.01.040_b0190","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.3389\/fimmu.2019.01787","article-title":"Remembrance of things past: long-term B cell memory after infection and vaccination","volume":"10","author":"Palm","year":"2019","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2021.01.040_b0195","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/cei.12044","article-title":"Protecting against plague: towards a next-generation vaccine","volume":"172","author":"Williamson","year":"2013","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.vaccine.2021.01.040_b0200","doi-asserted-by":"crossref","unstructured":"Levy Y, Vagima Y, Tidhar A, Aftalion M, Gur D, Nili U et al. Targeting of the Yersinia pestis F1 capsular antigen by innate-like B1b cells mediates a rapid protective response against bubonic plague. NPJ Vaccines 2018;3:52,z. eCollection 2018.","DOI":"10.1038\/s41541-018-0087-z"},{"issue":"5","key":"10.1016\/j.vaccine.2021.01.040_b0205","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1128\/CVI.00398-06","article-title":"Development of in vitro correlate assays of immunity to infection with Yersinia pestis","volume":"14","author":"Bashaw","year":"2007","journal-title":"Clin Vaccine Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2021.01.040_b0210","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/j.1600-0684.2010.00443.x","article-title":"Primary pneumonic plague in the African Green monkey as a model for treatment efficacy evaluation","volume":"40","author":"Layton","year":"2011","journal-title":"J Med Primatol"},{"issue":"5","key":"10.1016\/j.vaccine.2021.01.040_b0215","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1128\/IAI.00105-08","article-title":"Yersinia pestis caf1 variants and the limits of plague vaccine protection","volume":"76","author":"Quenee","year":"2008","journal-title":"Infect Immun"},{"issue":"13","key":"10.1016\/j.vaccine.2021.01.040_b0220","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1016\/j.vaccine.2005.11.047","article-title":"Respiratory immunity is an important component of protection elicited by subunit vaccination against pneumonic plague","volume":"24","author":"Reed","year":"2006","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2021.01.040_b0225","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.meegid.2009.10.003","article-title":"Amino acid and structural variability of Yersinia pestis LcrV protein","volume":"10","author":"Anisimov","year":"2010","journal-title":"Infect Genet Evol"},{"issue":"6","key":"10.1016\/j.vaccine.2021.01.040_b0230","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1128\/IAI.00185-06","article-title":"Gamma interferon, tumor necrosis factor alpha, and nitric oxide synthase 2, key elements of cellular immunity, perform critical protective functions during humoral defense against lethal pulmonary Yersinia pestis infection","volume":"74","author":"Parent","year":"2006","journal-title":"Infect Immun"},{"issue":"1","key":"10.1016\/j.vaccine.2021.01.040_b0235","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1128\/iai.61.1.23-31.1993","article-title":"Association between virulence of Yersinia pestis and suppression of gamma interferon and tumor necrosis factor alpha","volume":"61","author":"Nakajima","year":"1993","journal-title":"Infect Immun"},{"issue":"3","key":"10.1016\/j.vaccine.2021.01.040_b0240","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.4049\/jimmunol.1003303","article-title":"IL-17 contributes to cell-mediated defense against pulmonary Yersinia pestis infection","volume":"186","author":"Lin","year":"2011","journal-title":"J Immunol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21000670?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21000670?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:51:44Z","timestamp":1759402304000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X21000670"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":48,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["S0264410X21000670"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.01.040","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Single-dose intranasal subunit vaccine rapidly clears secondary sepsis in a high-dose pneumonic plague infection","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.01.040","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}